Early market access for unauthorized drugs in Italy: The value-based price for reimbursement decisions

A major challenge for regulatory agencies is balancing the need for rapid access to drugs for new indications against the limited information on their benefit–risk ratio. The processes described by Martinalbo and colleagues depicted a European scenario with different national frameworks [1].